Distribution and Drug Resistance of <i>Acinetobacter baumannii</i> Isolated from Inpatients in Ruijin Hospital from 2008 to 2012_West China Medical Journal

Authors：

 XUGui-ting , MIChen-rong , LIWen-hui , ZHANGYi-bo , GONGZheng-feng , NIYu-xing ,  WANGQun

Department of Nosocomial Infection Management, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China;

Corresponding author：

WANGQun, Email: wangqun83953@126.com

Keywords：

Acinetobacter baumannii; Clinical distribution; Drug resistance; Antimicrobial agents

DOI：

10.7507/1002-0179.20140125

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the clinical distribution and the change of drug resistance of Acinetobacter baumannii from different inpatient specimens sources during 2008 to 2012, and to provide guidance for rational use of antibiotics. Methods The identification of Acinetobacter baumannii was conducted by VITEK-2 based on clinical and laboratory standards institute (CLSI) guideline between January 2008 and December 2012. The susceptibility of antibiotics was determined by K-B test, and data analysis was conducted by Excel and SAS. Results A total of 3 139 stains of Acinetobacter baumannii were isolated from 2013 patients during this period. The Acinetobacter baumannii was mainly obtained from the Burn ward, Intensive Care Unit ward and Thoracic ward. Sputum was the most specimens of Acinetobacter baumannii, accounting for 48.4%. The drug resistance rates of Acinetobacter baumannii to most of the antimicrobial agents were more than 55%. Compound antibacterial is more effective than the single drug ingredient. Compared with other antimicrobial agents, β-lactams/β-lactamase inhibitor compound and carbapenems antimicrobial agents were more sensitive. Conclusion The drug resistance of Acinetobacter baumannii is serious and has differences among hospitals. Clinicians should monitor the drug resistance of Acinetobacter baumannii timely and choose proper antibiotics according to the results of drug sensitivity.

Citation： XUGui-ting, MIChen-rong, LIWen-hui, ZHANGYi-bo, GONGZheng-feng, NIYu-xing, WANGQun. Distribution and Drug Resistance of Acinetobacter baumannii Isolated from Inpatients in Ruijin Hospital from 2008 to 2012. West China Medical Journal, 2014, 29(3): 413-416. doi: 10.7507/1002-0179.20140125 Copy

1.	Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3):538-582.
2.	熊丽蓉, 刘耀, 谢林利, 等. 我院2006-2011年鲍曼不动杆菌临床分布及耐药性分析[J]. 中国药房, 2012, 23(46):4369-4370.
3.	徐惠, 马智超, 罗明, 等. 某三甲综合性医院20年间出院患者年龄结构变迁[J]. 中国卫生统计, 2013, 30(5):758-759.
4.	刘德新, 卢俊英, 田加坤, 等. 综合性ICU鲍曼不动杆菌肺部感染调查及耐药性分析[J]. 中国实验诊断学, 2013, 17(1):127-129.
5.	袁星, 沈继录, 徐元宏. 120株临床分离鲍曼不动杆菌感染的分布和耐药性分析[J]. 现代预防医学, 2011(10):1901-1903, 1907.
6.	罗鹏, 戴玮, 张莉萍. 1582株鲍曼不动杆菌的临床分布及耐药性分析[J]. 重庆医学, 2011(3):224-225, 228.
7.	Dai TH, Huang YY, Sulbha KS, et al. Topical antimicrobials for burn wound infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2):124-151.
8.	汪复, 朱德妹, 胡付品, 等. 2008年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2009, 9(5):321-329.
9.	汪复, 朱德妹, 胡付品, 等. 2009年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2010, 10(5):325-334.
10.	朱德妹, 汪复, 胡付品, 等. 2010年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2011, 11(5):321-329.
11.	胡付品, 朱德妹, 汪复, 等. 2011年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2012(5):321-329.
12.	汪复, 朱德妹, 胡付品, 等. 2012年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2013, 13(5):321-330.
13.	谈华, 邵海枫, 王锦娜, 等. 舒巴坦单剂及舒巴坦与第三代头孢菌素联合对鲍曼不动杆菌的体外抗菌作用比较[J]. 中国抗生素杂志, 2006, 31(8):488-491.
14.	Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322.
15.	李玉强, 万忠林. 我院1999年1月-2011年9月鲍曼不动杆菌的分布及耐药性分析[J]. 中国药房, 2012(6):529-531.
16.	唐晓铃, 杨缙. 重症监护病房鲍曼不动杆菌感染现状及耐药性分析[J]. 重庆医学, 2013, 42(3):302-303.
17.	李华, 申亚晖, 史跃杰. 重症医学科内感染患者病原菌的分布及鲍曼不动杆菌耐药分析[J]. 中国全科医学, 2012, 15(7):813-815.
18.	王辉, 郭萍, 孙宏莉, 等. 碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J]. 中华检验医学杂志, 2006(12):1066-1073.
19.	陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中国医药科学, 2012, 92(8):3-8.

1. Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3):538-582.
2. 熊丽蓉, 刘耀, 谢林利, 等. 我院2006-2011年鲍曼不动杆菌临床分布及耐药性分析[J]. 中国药房, 2012, 23(46):4369-4370.
3. 徐惠, 马智超, 罗明, 等. 某三甲综合性医院20年间出院患者年龄结构变迁[J]. 中国卫生统计, 2013, 30(5):758-759.
4. 刘德新, 卢俊英, 田加坤, 等. 综合性ICU鲍曼不动杆菌肺部感染调查及耐药性分析[J]. 中国实验诊断学, 2013, 17(1):127-129.
5. 袁星, 沈继录, 徐元宏. 120株临床分离鲍曼不动杆菌感染的分布和耐药性分析[J]. 现代预防医学, 2011(10):1901-1903, 1907.
6. 罗鹏, 戴玮, 张莉萍. 1582株鲍曼不动杆菌的临床分布及耐药性分析[J]. 重庆医学, 2011(3):224-225, 228.
7. Dai TH, Huang YY, Sulbha KS, et al. Topical antimicrobials for burn wound infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2):124-151.
8. 汪复, 朱德妹, 胡付品, 等. 2008年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2009, 9(5):321-329.
9. 汪复, 朱德妹, 胡付品, 等. 2009年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2010, 10(5):325-334.
10. 朱德妹, 汪复, 胡付品, 等. 2010年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2011, 11(5):321-329.
11. 胡付品, 朱德妹, 汪复, 等. 2011年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2012(5):321-329.
12. 汪复, 朱德妹, 胡付品, 等. 2012年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2013, 13(5):321-330.
13. 谈华, 邵海枫, 王锦娜, 等. 舒巴坦单剂及舒巴坦与第三代头孢菌素联合对鲍曼不动杆菌的体外抗菌作用比较[J]. 中国抗生素杂志, 2006, 31(8):488-491.
14. Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322.
15. 李玉强, 万忠林. 我院1999年1月-2011年9月鲍曼不动杆菌的分布及耐药性分析[J]. 中国药房, 2012(6):529-531.
16. 唐晓铃, 杨缙. 重症监护病房鲍曼不动杆菌感染现状及耐药性分析[J]. 重庆医学, 2013, 42(3):302-303.
17. 李华, 申亚晖, 史跃杰. 重症医学科内感染患者病原菌的分布及鲍曼不动杆菌耐药分析[J]. 中国全科医学, 2012, 15(7):813-815.
18. 王辉, 郭萍, 孙宏莉, 等. 碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J]. 中华检验医学杂志, 2006(12):1066-1073.
19. 陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中国医药科学, 2012, 92(8):3-8.

West China Medical Journal

Distribution and Drug Resistance of Acinetobacter baumannii Isolated from Inpatients in Ruijin Hospital from 2008 to 2012

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content